Pfizer Corporation

Warner-lambert Company

Yasuhiro Katsu

Chikara Uchida

Hirohide Noguchi

Satoru Iguchi

Makoto Kawai

Kana Kon-I

Hiroki Koike

Seiji Nukui

Yuji Shishido

Mikio Morita

Tomoki Kato

Takafumi Ikeda

Noriaki Murase

Hiroki Sone

Mitsuhiro Kawamura

Takashi Kojima

This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HTreceptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

Benzimidazolone compounds having 5-HT4 receptor agonistic activity

This invention provides a compound of the formula (I):or a pharmaceutically acceptable salt thereof, wherein These compounds have 5-HTreceptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

[object Object]

This invention provides a compound of the formula (I):or a pharmaceutically acceptable salt, amide or ester thereof, wherein Rrepresents a hydrogen atom or a halogen atom; Rrepresents a hydrogen atom, etc.; Rrepresents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of Ris substituted by at least one substituent selected from the group consisting of substituents &#x3b1;; said substituents &#x3b1; is aryl, hydroxy, oxo, etc.; said aryl having 6 to 10 carbon atoms; said aryl is unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents &#x3b1;, are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms These compounds have 5-HTreceptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators

N-benzenesulfonyl L-proline compounds as bradykinin antagonists

1,4-dihydropyridine compounds as bradykinin antagonists

Growing community of inventors

Taketoyo-cho, Japan

Yasuhiro Katsu